Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8041 to 8055 of 8885 results

  1. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued Reference number: GID-TA11209

    Technology appraisal guidance
    Discontinued

  2. Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

    Discontinued Reference number: GID-HST10004

    Highly specialised technologies guidance
    Discontinued

  3. Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

    Discontinued Reference number: GID-MT130

    Medical technologies guidance
    Discontinued

  4. Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

    Discontinued Reference number: GID-MT163

    Medical technologies guidance
    Discontinued

  5. Microthane implants for breast reconstruction or breast augmentation (discontinued)

    Discontinued Reference number: GID-MT267

    Medical technologies guidance
    Discontinued

  6. Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

    In development Reference number: GID-TA10589 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued Reference number: GID-TA11000

    Technology appraisal guidance
    Discontinued

  8. Insulin icodec for treating type 2 diabetes [ID6175]

    In development Reference number: GID-TA11104 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]

    Discontinued Reference number: GID-TA10996

    Technology appraisal guidance
    Discontinued

  10. Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]

    Discontinued Reference number: GID-TA10965

    Technology appraisal guidance
    Discontinued

  11. Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]

    Discontinued Reference number: GID-TA10863

    Technology appraisal guidance
    Discontinued

  12. Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]

    Discontinued Reference number: GID-TA10766

    Technology appraisal guidance
    Discontinued

  13. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued Reference number: GID-TA11244

    Technology appraisal guidance
    Discontinued

  14. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    Discontinued Reference number: GID-TA11255

    Technology appraisal guidance
    Discontinued

  15. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    Discontinued Reference number: GID-TA11204

    Technology appraisal guidance
    Discontinued